SELLAS Life Sciences Group 관리

관리 기준 확인 3/4

SELLAS Life Sciences Group CEO는 Angelos Stergiou, Dec2012 에 임명되었습니다 의 임기는 11.92 년입니다. 총 연간 보상은 $ 1.75M, 35.7% 로 구성됩니다. 35.7% 급여 및 64.3% 보너스(회사 주식 및 옵션 포함). 는 € 60.85K 가치에 해당하는 회사 주식의 0.081% 직접 소유합니다. 60.85K. 경영진과 이사회의 평균 재임 기간은 각각 4.8 년과 6.9 년입니다.

주요 정보

Angelos Stergiou

최고 경영자

US$1.8m

총 보상

CEO 급여 비율	35.7%
CEO 임기	11.9yrs
CEO 소유권	0.08%
경영진 평균 재임 기간	4.8yrs
이사회 평균 재임 기간	6.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Angelos Stergiou 의 보수는 SELLAS Life Sciences Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$32m
Jun 30 2024	n/a	n/a	-US$34m
Mar 31 2024	n/a	n/a	-US$36m
Dec 31 2023	US$2m	US$625k	-US$37m
Sep 30 2023	n/a	n/a	-US$38m
Jun 30 2023	n/a	n/a	-US$36m
Mar 31 2023	n/a	n/a	-US$36m
Dec 31 2022	US$2m	US$594k	-US$41m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	-US$39m
Mar 31 2022	n/a	n/a	-US$35m
Dec 31 2021	US$2m	US$565k	-US$21m
Sep 30 2021	n/a	n/a	-US$18m
Jun 30 2021	n/a	n/a	-US$15m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$1m	US$541k	-US$17m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$28m
Mar 31 2020	n/a	n/a	-US$27m
Dec 31 2019	US$1m	US$630k	-US$28m
Sep 30 2019	n/a	n/a	-US$34m
Jun 30 2019	n/a	n/a	-US$32m
Mar 31 2019	n/a	n/a	-US$36m
Dec 31 2018	US$1m	US$549k	-US$41m
Sep 30 2018	n/a	n/a	-US$37m
Jun 30 2018	n/a	n/a	-US$32m
Mar 31 2018	n/a	n/a	-US$30m
Dec 31 2017	US$729k	US$400k	-US$24m

보상 대 시장: Angelos 의 총 보상 ($USD 1.75M )은 German 시장( $USD 478.33K ).

보상과 수익: Angelos 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Angelos Stergiou (48 yo)

11.9yrs

테뉴어

US$1,752,638

보상

Dr. Angelos M. Stergiou, MD, Sc.D. h.c., is the Founder, President, Chief Executive Officer and Director of SELLAS Life Sciences Group, Inc. (formerly known as SELLAS Life Sciences Group AG) (formerly, Sel...

리더십 팀

이름	위치	테뉴어	보상	소유권
Angelos Stergiou	Founder	11.9yrs	US$1.75m	0.081% € 60.8k
John Burns	Senior VP & CFO	6.9yrs	US$797.71k	0.037% € 27.7k
Stacy Yeung	VP, Associate General Counsel & Head of Compliance	less than a year	데이터 없음	데이터 없음
Dragan Cicic	Senior Vice President of Clinical Development	4.8yrs	US$859.54k	0.040% € 30.0k
Andrew Elnatan	VP and Head of Regulatory Affairs	1.8yrs	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: RXK3 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Angelos Stergiou	Founder	11.9yrs	US$1.75m	0.081% € 60.8k
Robert Van Nostrand	Independent Director	6.9yrs	US$106.28k	0.0063% € 4.7k
John Varian	Independent Director	6.9yrs	US$110.50k	0.0063% € 4.7k
David Scheinberg	Independent Director	6.9yrs	US$102.50k	0.0065% € 4.9k
Jane Wasman	Independent Chairman	6.9yrs	US$136.28k	0.0063% € 4.7k
Jeffrey Weber	Chairman of Scientific Advisory Board	8yrs	데이터 없음	데이터 없음
Sattva Neelapu	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Larry W. Kwak	Member of Scientific Advisory Board	9yrs	데이터 없음	데이터 없음
Javier Pinilla-Ibarz	Member of Scientific Advisory Board	8yrs	데이터 없음	데이터 없음
Guenther Koehne	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Katherine Kalin	Independent Director	2.3yrs	US$92.50k	0.0063% € 4.7k

6.9yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 이사회: RXK3 의 이사회는 경험(평균 재직 기간 6.9 년)으로 간주됩니다.

SELLAS Life Sciences Group 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 20, 2024

SELLAS Life Sciences Group, Inc. Announces Executive Changes

SELLAS Life Sciences Group, Inc. Appoints John T. Burns as Chief Financial Officer

SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and Quality

Insufficient new directors

Insufficient new directors

Recent updates

SELLAS Life Sciences Group, Inc. Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

New major risk - Financial position

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

New major risk - Financial position

SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 20, 2024

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $19.999797 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering.

SELLAS Life Sciences Group, Inc. Announces Executive Changes

SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock Market

Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-S

New major risk - Negative shareholders equity

SELLAS Life Sciences Group, Inc. Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of galinpepimut-S in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at International Gynecologic Cancer Society 2023 Annual Global Meeting

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Provides Update on Phase 3 Regal Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas

New major risk - Share price stability

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data in Lymphoma Cohort from Sls009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met

New major risk - Financial position

SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma

Sellas Life Sciences Group, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial of GFH009 in Acute Myeloid Leukemia

Sellas Life Sciences Group, Inc. Announces Positive Topline Data from Gfh009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study

Full year 2022 earnings released: US$2.13 loss per share (vs US$1.34 loss in FY 2021)

SELLAS Life Sciences Group, Inc. Appoints John T. Burns as Chief Financial Officer

SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and Quality

SELLAS Life Sciences Group, Inc. Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies

SELLAS Life Sciences Group, Inc. ’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned

SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vivo Study

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021)

Insufficient new directors

SELLAS Life Sciences Group, Inc. Announces Update on Phase 3 Regal Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (Pembrolizumab) in Patients with Wt1+ Platinum-Resistant Advanced Ovarian Cancer

SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S

Insufficient new directors

SELLAS Life Sciences Group Announces Results from New Preclinical in Vitro Study for its Highly Selective CDK9 Inhibitor, GFH009

SELLAS Life Sciences Group, Inc. Announces Election of Katherine Bach Kalin to Its Board of Directors

Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.30 loss in 2Q 2021)

SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vitro Studies for CDK9 inhibitor, GFH009

SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009

SELLAS Life Sciences Group, Inc. Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial

SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo

SELLAS Life Sciences Group, Inc. Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

First quarter 2022 earnings released: US$1.05 loss per share (vs US$0.16 loss in 1Q 2021)

Insufficient new directors

SELLAS Life Sciences Group, Inc. Launches Expand Access Program for Galinpepimut-S

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 08, 2022

SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study

Sellas Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China

Sellas Life Sciences Group, Inc. Announces Final Court Approval of Settlement of Securities Litigation

SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer

SELLAS Life Sciences Group, Inc. Announces IND Acceptance for First Clinical Trial of GPS in China

SELLAS Life Sciences Group, Inc. Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer

SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo